{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:00:36Z","timestamp":1785254436768,"version":"3.55.0"},"reference-count":60,"publisher":"Bioscientifica","issue":"7","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatic arterial embolization reduces liver tumor burden and hormonal secretion in neuroendocrine tumors, but its safety in patients with carcinoid heart disease is underexplored, and current guidelines suggest managing the cardiac disease first. We assessed the safety and efficacy of hepatic arterial embolization in patients with neuroendocrine tumors and concomitant carcinoid heart disease in a single-center retrospective study including patients with liver metastases and carcinoid heart disease confirmed on expert transthoracic echocardiography between 2001 and 2025. The primary endpoint was procedural safety; secondary endpoints were symptom control, biochemical response, and overall survival. Twenty-seven patients (median age: 58.6 years) underwent 69 embolization procedures using bland, conventional, and drug-eluting bead techniques. Severe carcinoid heart disease was present in 52% of patients, and right-sided valvular disease was found in 96%, with tricuspid regurgitation predominating. No procedure-related or cardiovascular death occurred. Two cardiac complications (7%) arose, both in patients with severe pre-existing valvular disease, together with four extra-cardiac complications. Carcinoid syndrome symptoms and urinary 5-hydroxyindoleacetic acid levels decreased significantly after treatment, whereas cardiac symptoms remained stable. The median overall survival was 6.25 years, with a 5-year survival of 60%. Hepatic arterial embolization appears feasible with an acceptable safety profile in patients with neuroendocrine tumors and concomitant carcinoid heart disease when performed in expert centers with multidisciplinary management and may contribute to carcinoid syndrome control. Prospective multicenter studies are warranted to confirm these findings and define the optimal sequencing of hepatic arterial embolization and cardiac valve surgery.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p\/>\n                  <\/jats:sec>","DOI":"10.1530\/erc-26-0128","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:02:57Z","timestamp":1783944177000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic arterial embolization procedures in neuroendocrine tumors with carcinoid heart disease: a retrospective single-center study on safety and feasibility"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4220-4552","authenticated-orcid":true,"given":"Th\u00e9odore","family":"Vuong","sequence":"first","affiliation":[{"name":"D\u00e9partement d\u2019Anesth\u00e9sie Chirurgie et Interventionnel (DACI), Service d\u2019Imagerie Th\u00e9rapeutique, Gustave Roussy 1 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Tselikas","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Anesth\u00e9sie Chirurgie et Interventionnel (DACI), Service d\u2019Imagerie Th\u00e9rapeutique, Gustave Roussy 1 , ,","place":["Villejuif, France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Saclay 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-3289","authenticated-orcid":true,"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Oncologique, Gustave Roussy 3 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sond\u00e9s","family":"Smaali","sequence":"additional","affiliation":[{"name":"Institut d\u2019Oncologie Thoracique, H\u00f4pital Marie Lannelongue 4 , ,","place":["Le Plessis-Robinson, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Anesth\u00e9sie Chirurgie et Interventionnel (DACI), Service de Chirurgie Digestive, Gustave Roussy 5 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"De Ba\u00e8re","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Anesth\u00e9sie Chirurgie et Interventionnel (DACI), Service d\u2019Imagerie Th\u00e9rapeutique, Gustave Roussy 1 , ,","place":["Villejuif, France"]},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Saclay 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Oncologique, Gustave Roussy 3 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Moog","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Oncologique, Gustave Roussy 3 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fernandez De Sevilla","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Anesth\u00e9sie Chirurgie et Interventionnel (DACI), Service de Chirurgie Digestive, Gustave Roussy 5 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Beunon","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Anesth\u00e9sie Chirurgie et Interventionnel (DACI), Service d\u2019Imagerie Th\u00e9rapeutique, Gustave Roussy 1 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re 6 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Menu","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Imagerie M\u00e9dicale, Service de Radiologie Diagnostique, Gustave Roussy 7 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Deschamps","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Anesth\u00e9sie Chirurgie et Interventionnel (DACI), Service d\u2019Imagerie Th\u00e9rapeutique, Gustave Roussy 1 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Baudin","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Oncologique, Gustave Roussy 3 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Bonnet","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Anesth\u00e9sie Chirurgie et Interventionnel (DACI), Service d\u2019Imagerie Th\u00e9rapeutique, Gustave Roussy 1 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"2026072811210873600_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7861\/clinmed.2023-0044","article-title":"Diagnosis and management of neuroendocrine tumours","volume":"23","author":"Cuthbertson","year":"2023","journal-title":"Clin Med"},{"key":"2026072811210873600_bib2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026072811210873600_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000442207","article-title":"Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010","volume":"104","author":"Boyar Cetinkaya","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2026072811210873600_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of neuroendocrine neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026072811210873600_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026072811210873600_bib6","doi-asserted-by":"crossref","first-page":"R417","DOI":"10.1530\/ERC-20-0122","article-title":"Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison","volume":"27","author":"Kasajima","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"2026072811210873600_bib7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jamaoncol.2024.4330","article-title":"Biomarkers to inform prognosis and treatment for unresectable or metastatic GEP-NENs","volume":"10","author":"Loree","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026072811210873600_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejca.2022.06.003","article-title":"Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms","volume":"172","author":"Pole\u00e9","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026072811210873600_bib9","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026072811210873600_bib10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"2026072811210873600_bib11","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026072811210873600_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026072811210873600_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/endrev\/bnad035","article-title":"What is carcinoid syndrome? A critical appraisal of its proposed mediators","volume":"45","author":"Mulders","year":"2024","journal-title":"Endocr Rev"},{"key":"2026072811210873600_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13262","article-title":"Carcinoid heart disease in patients with midgut neuroendocrine tumours","volume":"35","author":"Delhomme","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026072811210873600_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000549211","article-title":"Diagnosis and treatment of right-sided valve disease in cardiac carcinoid syndrome: a systematic review","author":"Louren\u00e7o","year":"2025","journal-title":"Cardiology"},{"key":"2026072811210873600_bib16","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jacc.2015.09.014","article-title":"Early and late outcomes of surgical treatment in carcinoid heart disease","volume":"66","author":"Connolly","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026072811210873600_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mayocp.2025.01.026","article-title":"Impact of tumor burden and cardiac factors on survival after valve surgery for carcinoid heart disease","volume":"101","author":"Sawma","year":"2026","journal-title":"Mayo Clin Proc"},{"key":"2026072811210873600_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/oncolo\/oyad126","article-title":"Carcinoid heart disease management: a multi-disciplinary collaboration","volume":"28","author":"Das","year":"2023","journal-title":"Oncologist"},{"key":"2026072811210873600_bib19","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cncr.28760","article-title":"Therapeutic strategies for neuroendocrine liver metastases","volume":"121","author":"Frilling","year":"2015","journal-title":"Cancer"},{"key":"2026072811210873600_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000461583","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy","volume":"105","author":"Kaltsas","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2026072811210873600_bib21","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1530\/ERC-18-0495","article-title":"Management of carcinoid syndrome: a systematic review and meta-analysis","volume":"26","author":"Hofland","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026072811210873600_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026072811210873600_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"ENETS 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"2026072811210873600_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1148\/radiol.11081489","article-title":"Transcatheter intraarterial therapies: rationale and overview","volume":"259","author":"Lewandowski","year":"2011","journal-title":"Radiology"},{"key":"2026072811210873600_bib25","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.3390\/cancers13215366","article-title":"Long term efficacy and assessment of tumor response of transarterial chemoembolization in neuroendocrine liver metastases: a 15-year monocentric experience","volume":"13","author":"Touloupas","year":"2021","journal-title":"Cancers"},{"key":"2026072811210873600_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.03.002","article-title":"Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions","volume":"66","author":"Tapia","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2026072811210873600_bib27","doi-asserted-by":"crossref","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072811210873600_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"2026072811210873600_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/OP-25-00133","article-title":"Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"22","author":"Perez","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"2026072811210873600_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jvir.2015.12.752","article-title":"Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria","volume":"27","author":"Gaba","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"2026072811210873600_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000225947","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography","volume":"90","author":"Pl\u00f6ckinger","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2026072811210873600_bib32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4183\/aeb.2024.412","article-title":"WHO classification of endocrine and neuroendocrine tumours, 5th edition - Who Classification of Tumours, Volume 10","volume":"20","author":"Corin","year":"2024","journal-title":"Acta Endocrinol (Buchar)"},{"key":"2026072811210873600_bib33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00428-017-2276-y","article-title":"Eighth edition of the UICC classification of malignant tumours: an overview of the changes in the pathological TNM classification criteria-what has changed and why?","volume":"472","author":"Bertero","year":"2018","journal-title":"Virchows Arch"},{"key":"2026072811210873600_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"2026072811210873600_bib35","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026072811210873600_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2026072811210873600_bib37","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jvir.2016.05.014","article-title":"Conventional versus drug-eluting bead transarterial chemoembolization for neuroendocrine tumor liver metastases","volume":"27","author":"Makary","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"2026072811210873600_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","article-title":"Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads","volume":"56","author":"Guiu","year":"2012","journal-title":"J Hepatol"},{"key":"2026072811210873600_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00270-012-0424-y","article-title":"Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases","volume":"36","author":"Bhagat","year":"2013","journal-title":"Cardiovasc Interv Radiol"},{"key":"2026072811210873600_bib40","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in advanced carcinoid tumors: ECOG study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026072811210873600_bib41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-015-1208-y","article-title":"Treatment of liver tumors with Lipiodol TACE: technical recommendations from experts opinion","volume":"39","author":"de Baere","year":"2016","journal-title":"Cardiovasc Interv Radiol"},{"key":"2026072811210873600_bib42","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00270-011-0287-7","article-title":"Transcatheter treatment of HCC with doxorubicin-loaded DC bead (DEBDOX): technical recommendations","volume":"35","author":"Lencioni","year":"2012","journal-title":"Cardiovasc Interv Radiol"},{"key":"2026072811210873600_bib43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.seminoncol.2010.03.004","article-title":"Transarterial liver-directed therapies of neuroendocrine hepatic metastases","volume":"37","author":"Nazario","year":"2010","journal-title":"Semin Oncol"},{"key":"2026072811210873600_bib44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2011-0372","article-title":"Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications","volume":"17","author":"Lewis","year":"2012","journal-title":"Oncologist"},{"key":"2026072811210873600_bib45","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1245\/s10434-025-18287-5","article-title":"Contemporary short-term outcomes of liver-directed therapy for neuroendocrine tumor liver metastases","volume":"32","author":"Meloche-Dumas","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2026072811210873600_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"key":"2026072811210873600_bib47","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1530\/EC-19-0269","article-title":"Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection","volume":"8","author":"Calanchini","year":"2019","journal-title":"Endocr Connect"},{"key":"2026072811210873600_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13060","article-title":"Synoptic reporting of echocardiography in carcinoid heart disease (ENETS carcinoid heart disease task force)","volume":"34","author":"Hofland","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"2026072811210873600_bib49","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1245\/s10434-016-5333-x","article-title":"Transarterial chemoembolization for metastatic neuroendocrine tumors with massive hepatic tumor burden","volume":"23","author":"Kitano","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2026072811210873600_bib50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jamcollsurg.2019.12.026","article-title":"Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis","volume":"230","author":"Egger","year":"2020","journal-title":"J Am Coll Surg"},{"key":"2026072811210873600_bib51","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/RCT.0000000000001610","article-title":"Spectrum of imaging findings and complications after hepatic transarterial chemoembolization for liver tumors","volume":"48","author":"Zandieh","year":"2024","journal-title":"J Comput Assist Tomogr"},{"key":"2026072811210873600_bib52","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.surg.2021.02.054","article-title":"Outcomes of surgical treatment for carcinoid heart disease: a systematic review and meta-analysis","volume":"170","author":"O\u2019Malley","year":"2021","journal-title":"Surgery"},{"key":"2026072811210873600_bib53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/heartjnl-2023-322945","article-title":"Management and outcomes of carcinoid heart disease with liver metastases of midgut neuroendocrine tumours","volume":"110","author":"Suc","year":"2023","journal-title":"Heart"},{"key":"2026072811210873600_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13199","article-title":"Four decades of experience with carcinoid heart disease: an analysis of 84 patients","volume":"34","author":"Levy","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"2026072811210873600_bib55","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1161\/CIRCULATIONAHA.105.553750","article-title":"Prognosis of carcinoid heart disease: analysis of 200 cases over two decades","volume":"112","author":"M\u00f8ller","year":"2005","journal-title":"Circulation"},{"key":"2026072811210873600_bib56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"key":"2026072811210873600_bib57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12020-018-1537-0","article-title":"Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice","volume":"60","author":"Grozinsky-Glasberg","year":"2018","journal-title":"Endocrine"},{"key":"2026072811210873600_bib58","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.11226","article-title":"Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor","volume":"97","author":"Zuetenhorst","year":"2003","journal-title":"Cancer"},{"key":"2026072811210873600_bib59","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s002689900136","article-title":"Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction","volume":"20","author":"W\u00e4ngberg","year":"1996","journal-title":"World J Surg"},{"key":"2026072811210873600_bib60","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/ejcts\/ezr227","article-title":"Carcinoid heart disease: outcomes after surgical valve replacement","volume":"41","author":"Mokhles","year":"2012","journal-title":"Eur J Cardio Thorac Surg"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0128\/521904\/erc-26-0128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0128\/521904\/erc-26-0128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:21:20Z","timestamp":1785252080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/7\/e260128\/77794\/Hepatic-arterial-embolization-procedures-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0128","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"e260128"}}